Clinical Trial Update: Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the combination of cetuximab with afatinib in patients with EGFR-mutated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• Cetuximab (cetuximab)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED